Omeros reports Q3 2026 results, CHMP negative opinion on narsoplimab in Europe
YARTEMLEA U.S. sales rose as the company outlined 2026-2027 trial starts for OMS1029, OMS527, and OncotoX-AML, while Novo's zaltenibart Phase 3 stays on track.
Omeros Corporation reported third quarter 2026 results on November 16, 2026. In the U.S., New Technology Add-on Payment status for YARTEMLEA became effective on October 1, 2026, providing eligible hospitals up to $287,079 in additional Medicare reimbursement per eligible inpatient case.1
On the pipeline, Omeros said it expects to support two investigator-initiated or company co-sponsored studies of YARTEMLEA, one in hyperinflammatory ARDS and one in prevention of TA-TMA in high-risk pediatric transplant patients, each open-label and single-arm with about 50 to 60 patients, with initiation anticipated in late 2026 or early 2027 subject to IRB and ethics approvals.1 The company is finalizing the initial indication for a Phase 2 program for OMS1029, its long-acting MASP-2 antibody.1 For OMS527 in cocaine use disorder, Omeros is conducting a nonclinical study requested by FDA before starting the inpatient clinical trial, with enrollment expected to begin in the first quarter of 2027.1 The OncotoX-AML program's first-in-human Phase 1b trial of OMS805 is targeted to begin in late 2027, with IND-enabling studies and manufacturing underway.1
Financially, YARTEMLEA gross revenue was $41.8 million in the third quarter, up 30% from $32.2 million in the second quarter, with net revenue up 26% to $35.9 million from $28.5 million.1 GAAP net loss was $57.4 million, or $0.79 per share, including a $62.0 million non-cash loss tied to mark-to-market adjustments on the 2029 Notes derivative.1 The second quarter's comparison figure was GAAP net income of $13.2 million, or $0.18 per share, which included a non-cash gain of $11.4 million from the same mark-to-market adjustments.1 Omeros held $95.3 million in cash and short-term investments at September 30, 2026, and generated $13.3 million in positive operating cash flow for the quarter.1
Fact check notes
- Checker's noteThe summary line frames OMS1029 as having a '2026-2027 trial start' alongside OMS527 and OncotoX-AML, but the source gives no specific start date for OMS1029's Phase 2 program—only that the indication is being finalized.
- Sentence removed
In Europe, in October 2026 the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on Omeros' marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion adopted in June 2026.
copied source wording - Sentence removed
Partner Novo's zaltenibart MASP-3 inhibitor program is on track for Phase 3 trial initiation.
a corporate relationship the sources do not state
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.